Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;40(1):108-120.
doi: 10.1002/mds.30055. Epub 2024 Nov 18.

18F-Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

Gan Tang  1 , Jia-Ying Lu  2 , Xin-Yi Li  1 , Rui-Xin Yao  1 , Yu-Jie Yang  3 , Fang-Yang Jiao  2 , Ming-Jia Chen  1 , Xiao-Niu Liang  1   4 , Zi-Zhao Ju  2 , Jing-Jie Ge  2 , Yi-Xin Zhao  1 , Bo Shen  1 , Ping Wu  2 , Yi-Min Sun  1 , Jian-Jun Wu  1 , Tzu-Chen Yen  5 , Chuantao Zuo  2 , Jian Wang  1 , Qian-Hua Zhao  1   4   6 , Hui-Wei Zhang  2 , Feng-Tao Liu  1 ; Shanghai Memory Study (SMS) and Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI)
Collaborators, Affiliations

18F-Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

Gan Tang et al. Mov Disord. 2025 Jan.

Abstract

Background: Dementia with Lewy bodies (DLB) commonly exhibits a complex neuropathology, sharing characteristics with Alzheimer's disease (AD), including tau aggregates. However, studies using the 18F-AV-1451 tau tracer have shown inconsistent findings regarding both the extent and topographical distribution of tau pathology in DLB.

Objectives: Our aim was to elucidate the topographical patterns of tau deposition in DLB and to investigate the in vivo pathological distinction between DLB and AD in virtue of the 18F-Florzolotau positron emission tomography (PET) imaging.

Methods: This cross-sectional study enrolled patients with DLB (n = 24), AD (n = 43), and cognitively healthy controls (n = 18). Clinical assessments and 18F-Florzolotau PET imaging were performed. 18F-Florzolotau binding was quantitatively assessed on PET images using standardized uptake value ratios and voxel-wise analysis.

Results: 18F-Florzolotau PET imaging revealed widespread tau deposition across various cortical regions in DLB, uncovering heterogeneous topographical patterns. Among patients, 54.17% showed patterns similar to AD, whereas 16.67% exhibited distinct patterns. Compared to AD, DLB exhibited a unique in vivo neuropathological profile, characterized by a lower tau protein burden, heterogeneous topographical distributions, and a specific role of the medial temporal lobe in tau pathology.

Conclusions: 18F-Florzolotau PET imaging elucidated tau pathology patterns in DLB, providing valuable insights for future in vivo pathological differentiation and potential disease-modifying therapies. © 2024 International Parkinson and Movement Disorder Society.

Keywords: 18F‐Florzolotau; Alzheimer's disease; dementia with Lewy bodies; positron emission tomography; tau.

PubMed Disclaimer

References

    1. Bousiges O, Blanc F. Biomarkers of dementia with Lewy bodies: differential diagnostic with Alzheimer's disease. Int J Mol Sci 2022;23(12):6371. https://doi.org/10.3390/ijms23126371
    1. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005;34(6):561–566. https://doi.org/10.1093/ageing/afi190
    1. Armstrong MJ. Advances in dementia with Lewy bodies. Ther Adv Neurol Disord 2021;14:17562864211057666. https://doi.org/10.1177/17562864211057666
    1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89(1):88–100. https://doi.org/10.1212/WNL.0000000000004058
    1. Bousiges O, Blanc F. Diagnostic value of cerebro‐spinal fluid biomarkers in dementia with lewy bodies. Clin Chim Acta 2019;490:222–228. https://doi.org/10.1016/j.cca.2018.11.027

Substances

LinkOut - more resources